13 research outputs found
Accuracy and Precision of Dilution Procedure for Exe.
<p>*Expressed as mean percentage (n = 4) of the mean value measured over the nominal value</p><p><sup>#</sup>Expressed as percentage of the standard deviation divided by the mean</p><p>Accuracy and Precision of Dilution Procedure for Exe.</p
Mean concentrations of a) Exe (b) 17DhExe and (c) Exe17Oglu in plasma samples of one representative breast cancer patient.
<p>Mean concentrations of a) Exe (b) 17DhExe and (c) Exe17Oglu in plasma samples of one representative breast cancer patient.</p
Product ion mass spectra of (a) Exe (b) 17DhExe and (c) Exe17Oglu.
<p>Product ion mass spectra of (a) Exe (b) 17DhExe and (c) Exe17Oglu.</p
Representative chromatograms of (a) Exe (b) 17DhExe and (c) Exe17Oglu at LLOQ and (a) Exe-d3, (b) DhExe-d3 as well as Exe17Oglu at 100 ng/mL as internal standards.
<p>Representative chromatograms of (a) Exe (b) 17DhExe and (c) Exe17Oglu at LLOQ and (a) Exe-d3, (b) DhExe-d3 as well as Exe17Oglu at 100 ng/mL as internal standards.</p
UGT1A1 expression on belinostat glucuronidation and impact of the common UGT1A1*28 promoter polymorphism.
<p>A: Correlation of belinostat glucuronide formation with UGT1A1 expression in human liver microsomes; B: Belinostat glucuronide formation by human liver microsomes according to wild-type, heterozygous and homozygous UGT1A1*28 genotypes.</p
Identification of belinostat metabolites in human plasma using HPLC-DAD & LC-MS/MS analyses.
<p>Identification of belinostat metabolites in human plasma using HPLC-DAD & LC-MS/MS analyses.</p
Cytotoxicity and acetylation activity on HepG2.
<p>a: belinostat incubation; b: belinostat-G incubation; (templates for concentrations added (lower) and results of 24-well dose-increasing concentrations on HepG2 Cells (upper). c: MTS results for belinostat (IC<sub>50</sub> = 6.4 µM) and belinostat-G (cannot be converged). d:Belinostat acetylation activity on HepG2 cells (western blot). A: Acetyl histone 3 increased with dose increment after 5 h incubation; B: Kinetic changes of acetyl histone 3 with time increment at 10 µM.</p
Pharmacokinetic parameters for belinostat after 30 min i.v. infusion in Phase I trial.
<p>Abbreviation: Cmax, maximum concentration; Tmax, time to maximum concentration; AUC<sub>0–24 h,</sub> area under the curve from 0 to 24 h; T<sub>1/2</sub>, half-life at the elimination phase; CL, clearance; Vz, volume of distribution. *Mean ± SD; AUC ratio was calculated based on AUC<sub>0–24 h</sub> of Bel-G (belinostat-G) over AUC<sub>0–24 h</sub> of Bel (belinostat).</p
Identification of belinostat metabolites in human plasma using HPLC-UV at maximum absorption wavelength (λ = 268 nm).
<p>Chromatogram at day 5 and day 22 (A); day1(B).</p